New Frontiers in Lipid Management: The Role of Inclisiran in Cardiovascular Risk Reduction
| dc.contributor.advisor | Pórszász, Róbert | |
| dc.contributor.advisordept | Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | |
| dc.contributor.author | Gabr, Mariem Wael Mohamed Abdelrahman | |
| dc.contributor.department | DE--Általános Orvostudományi Kar | |
| dc.contributor.opponent | Szentmiklósi, József | |
| dc.contributor.opponent | Halasi , Barbara Dóra | |
| dc.contributor.opponentdept | Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | |
| dc.contributor.opponentdept | Általános Orvostudományi Kar::Igazságügyi Orvostani Intézet | |
| dc.date.accessioned | 2026-04-29T07:30:01Z | |
| dc.date.available | 2026-04-29T07:30:01Z | |
| dc.date.created | 2026-04-22 | |
| dc.description.abstract | Cardiovascular disease remains the leading cause of global mortality, with elevated LDL cholesterol identified as a key modifiable risk factor. Despite the availability of statins and other lipid lowering therapies, a significant proportion of high risk patients fail to reach guideline recommended LDL-C targets due to variable reasons. With continued research, novel therapeutic approaches targeting the PCSK9 pathway have emerged, most notably Inclisiran, the first approved siRNA based lipid lowering therapy. This thesis was written to review the biology of lipid metabolism and PCSK9, the mechanism of action of Inclisiran via RNA interference and hepatocyte selective delivery, and its clinical efficacy and safety as established through the ORION trial program, with a focus on its positioning relative to existing lipid lowering therapies as a potentially transformative advancement in cardiovascular risk management. | |
| dc.description.course | általános orvos | |
| dc.description.courselang | angol | |
| dc.description.degree | egységes, osztatlan | |
| dc.format.extent | 49 | |
| dc.identifier.uri | https://hdl.handle.net/2437/406617 | |
| dc.language.iso | en | |
| dc.rights.info | Hozzáférhető a 2022 decemberi felsőoktatási törvénymódosítás értelmében. | |
| dc.subject | Inclisiran | |
| dc.subject | siRNA | |
| dc.subject | Cardiovascular risk reduction | |
| dc.subject | Lipid management | |
| dc.subject.dspace | Medicine::Pharmacology | |
| dc.subject.dspace | Medicine::Cardiology | |
| dc.subject.dspace | Biology::Biochemistry | |
| dc.title | New Frontiers in Lipid Management: The Role of Inclisiran in Cardiovascular Risk Reduction |
Fájlok
Eredeti köteg (ORIGINAL bundle)
1 - 1 (Összesen 1)
Nincs kép
- Név:
- THESIS.pdf
- Méret:
- 528.01 KB
- Formátum:
- Adobe Portable Document Format
- Leírás:
- Thesis
Engedélyek köteg
1 - 1 (Összesen 1)
Nincs kép
- Név:
- license.txt
- Méret:
- 1.94 KB
- Formátum:
- Item-specific license agreed upon to submission
- Leírás: